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Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE) since it is the major
predictor of poor prognosis. In susceptible individuals suﬀering of SLE, in situ formation and deposit of immune complexes (ICs)
from apoptotic bodies occur in the kidneys as a result of an amplified epitope immunological response. IC glomerular deposits
generate release of proinflammatory cytokines and cell adhesion molecules causing inflammation. This leads to monocytes and
polymorphonuclear cells chemotaxis. Subsequent release of proteases generates endothelial injury and mesangial proliferation.
Presence of ICs promotes adaptive immune response and causes dendritic cells to release type I interferon. This induces maturation
and activation of infiltrating T cells, and amplification of Th2, Th1 and Th17 lymphocytes. Each of them, amplify B cells and
activates macrophages to release more proinflammatory molecules, generating eﬀector cells that cannot be modulated promoting
kidney epithelial proliferation and fibrosis. Herein immunopathological findings of LN are reviewed.
1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoim-
mune disease in which diverse immunological events can
lead to a similar clinical picture, characterized by a wide
range of clinical manifestations and target organs (pheno-
types) with unpredictable flares and remissions that even-
tually lead to permanent injury. Sociodemographic factors
such as sex, race, and ethnicity play an important role in the
incidence of the disease, frequency of its manifestations, and
therapeutic response.
The overall prevalence and incidence of SLE ranges from
1.4 to 21.9% and from 7.4 to 159.4 cases per 100,000 people,
respectively [1]. SLE can aﬀect several organs and systems,
including the joints, skin, brain, heart, lungs, blood vessels,
and kidneys.
Lupus nephritis (LN) is one of themost serious SLE com-
plications since it is the major predictor of poor prognosis.
The incidence and prevalence of LN varies depending on the
studied population. The LN cumulative incidence is higher
in people of Asian (55%), African (51%), and Hispanic
(43%) ancestry compared with Caucasians (14%) (1). Up to
25% of these patients still develop end-stage renal disease
(ESRD) 10 years after onset of renal compromise [2]. In
terms of outcome, the 5- and 10-year renal survival rates
of LN in the 1990s ranged between 83–93% and 74–84%,
respectively [2]. In addition, LN develops early in the course
of SLE thus becoming a major predictor of poor prognosis
[3]. However, in about 5% of the cases, LN may appear
several years after the onset of SLE (i.e., delayed LN) [4]. The
group with delayed LN is positively associated with Sjo¨gren
syndrome (SS), lung involvement, and antiphospholipid
syndrome as compared with early LN (i.e., those SLE patients
who develop LN during the first 5 years of the disease) [4].
LN has been looked upon as a classic example of im-
mune complex-induced microvascular injury which results
from circulating double-stranded DNA polynucleotide anti-
gens/anti-DNA antibody complexes and other mechanisms
including in situ reactivity for free antibodies with fixed
antigens and the presence of sensitized T cells which are an
important part of the picture [5]. Early deposits of immune
complexes (ICs) include nucleosomes, DNA-extractable
nuclear antigen antibodies (ENAS), and antibodies against
C1q complex of the complement system as byproducts of
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ineﬃcient phagocytosis of apoptotic bodies. This results in
an autoimmune response through epitope expansion. These
ICs have predominance over immunoglobulin G (IgG) 2
and 3. Deposits of ICs are initially located at the glomerular
mesangium and interstitial tissue within the proximal tubu-
lar epithelial cells (PTECs) [5]. These deposited ICs initiate
the release of proinflammatory cytokines and chemokines
such as monocyte chemoattractant protein-1 (MCP-1) and
cell adhesion molecules (CAMs) thus establishing a chronic
inflammatory process. The resulting overload of the mesan-
gial phagocytic system leads to deposits of subendothelial
ICs becoming an easy target for monocyte migration and
infiltration [5]. This migration and infiltration is due to a
general response of the innate immune system that releases
inflammatory proteases thus causing endothelial injury and
proliferation. In turn, the innate immune system response
promotes the activation of adaptive immune system sec-
ondary to the presence of ICs and dendritic cells (DCs),
which subsequently trigger release of type 1 interferon and
induce maturation and activation of infiltrating T cells. This
activation leads to sequential amplification of T helper 2 lym-
phocytes, (Th2) T helper 1 (Th1), and T helper 17 (Th17).
Each of these amplifies lymphocyte B cell response, and
activates macrophages. This generates a second general re-
sponse, which increases recruitment of eﬀector cells that can
no longer be modulated by regulatory T cells and, in the end,
results in epithelial glomerular proliferation and fibrosis [5]
(Figure 1).
2. Factors Influencing LN: Role of Ethnicity
So far, it has been diﬃcult to predict the course of LN. Renal
compromise in SLE has been markedly heterogeneous in
terms of clinical presentation and course. One of the most
important factors influencing LN is ethnicity. Prevalence
in populations varies depending on ethnicity. In a recent
case control study, Siso´ et al. found an overall prevalence
of 31% of LN in a large cohort of white Spanish biopsy-
proven patients. One third of these patients developed end-
stage renal disease (ESRD) [6]. Most studies have reported
rates of up to 31% ESRD in Africans and 18% in Hispanics
compared to 10% ESRD in Caucasians [7]. However, more
than a decade ago, Molina et al. described African and Latin
American patients with LN in a study with cohorts of 222 and
300 patients, respectively, which showed a higher prevalence
of LN 46% for both populations [8].
SLE patients from 9 diﬀerent Latin American coun-
tries were evaluated in the GLADEL Multinational Latin
American Prospective Inception Cohort of 1,214 Patients in
2004. Amongst the statistical significant results; Afro Latin
Americans (ALA) mestizos had more severe disease than did
whites, as evidenced by a higher frequency of renal disease,
pericarditis, polyadenopathy, and discoid lesions in ALA.
In addition, both ALA and mestizos had higher maximum
disease activity indices than whites, but this was lost when
controlled by country. However, damage scores tended to be
lower in ALA than in both mestizos and whites, a surprising
finding that might be explained by shorter disease duration
or by the more recent incorporation of Brazilian and Cuban
groups into the study. A peculiar observation was that of
a significantly lower frequency of both xerophthalmia and
sicca syndrome [8].
3. Murine Models
3.1. Spontaneous Murine Models. There has been a renewed
interest in the use of animal models in the study of IC medi-
ated LN, which has focused on immune and inflammatory
mechanisms involved in the disease process. The majority of
the murine models have been created to mimic LN [9]. This
research has led to a better understanding of the disease by
learning about the role of new cells and molecules that have
been involved in the pathogenesis of LN. There are many
known lupus murine models, which include spontaneous
mice with inherited susceptibility, transgenic, and deletion
knockout mouse models [9].
Specifically, three spontaneous lupus (inherited sus-
ceptibility) mouse models have been extensively studied:
New Zealand Black (NZB), New Zealand White F1 mice
(NZWF1), inbred strains of mice (BXSB), and mice homo-
zygous for the apoptosis-defective Faslpr mutation (MRL-
Faslpr). These models share some similarities with human
SLE including the presence of antinuclear antibodies
(ANAs), ICs, activation of T and B cells, and kidney disease.
Nevertheless, there are sharp diﬀerences in the genetic
origin and target organ involvement in murine models. The
MRLmice are the result of a mutation of Fas with diminished
apoptosis in lymphocytes, which generates hyper prolifera-
tion and secondary organomegaly [9, 10].
3.2. Transgenic Mice Models. Transgenic as well as deficient
(knockout) models have clarified the function of many mol-
ecules as well as their potential role in autoimmunity. This,
however, does not necessarily mean that these genes are rel-
evant to human SLE. For instance, deletion of the Fc receptor
in immunoglobulins (FcR) in NZB mice prevents injury
despite the deposit of ICs [11, 12]. The above result is
consistent with the fact that anti-DNA antibodies can mod-
ulate gene expression in mesangial cells through Fc-gamma-
receptor- (FcγR-) dependent and independent pathways,
which can induce proliferation, extracellular matrix synthe-
sis, and production of proinflammatory cytokines [13, 14].
Transgenicmodels with deleted genes (knockoutmodels)
have altered tolerance to B cells or T cells. These gene
deletions include FcγR, Bim, CD22, Lyn, (src-tyrosine kinase
involved in B-cell activation) CD72, and co-stimulatory
receptor (PD-1). In the MRL model, the removal of interac-
tions of the programmed death 1/programmed death ligand
1 (PD-1/PD-L1) pathway provided a negative regulatory
checkpoint in mediating tolerance and autoimmune disease.
PD-L1 caused early death by autoimmune myocarditis and
pneumonitis [15]. In addition, Lyn gene deletion in trans-
genic models aﬀects the ability of B cell receptors (BCR) to
edit. A T cell role has been demonstrated to be implicated
in LN through the deletion of CD4+ T cells in transgenic
models. The CD28 molecule, in turn, appears to be essential
to initiate the activation of lymphocyte CD4 + T cells and
also to induce costimulatory proteins (ICOS), which are
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Figure 1: Lupus nephritis: an imbalance between cytokine homeostasis and immune complex deposition. In predisposing susceptible
individuals who develop systemic lupus erythematosus (SLE), there is an acquired poor clearance of apoptotic bodies and a diminished
phagocytic capacity by macrophages (1). Early formation of immune complexes (ICs) include antinucleosomes, anti-double-stranded DNA
(anti-dsDNA), DNA extractable nuclear antigen antibodies (ENAS), antibodies against C1q complex of the complement system, free DNA,
antiribonucleoproteins (anti-RNP), and histones as byproducts of ineﬃcient phagocytosis of apoptotic bodies (2). Circulating ICs are
deposited initially at the glomerular base membrane (GBM), mesangium, and interstitial tissue within the proximal tubular epithelial cells
(PTECs) (3) and (4). The deposited ICs initiate the release of proinflammatory cytokines and chemokines such as monocyte chemoattractant
protein 1 (MCP-1), interleukins 1 and 6 (IL-1, IL-6) and adhesion molecules (CAMs) thus establishing a chronic inflammatory process (5).
The resulting overload of the mesangial phagocytic system (innate immune system) leads to deposits of subendothelial ICs becoming an easy
target for monocyte migration and infiltration and generating endothelial injury and proliferation (6) and (7). In turn, the adaptive immune
system is activated secondary to the presence of ICs and dendritic cells (DCs) (8), which subsequently trigger release of type 1 interferon
and induce maturation and activation of infiltrating T cells. This activation leads to sequential amplification of T helper 2 lymphocytes
(Th2), T helper 1 (Th1), and T helper 17 (Th17) (9). Each of these amplifies lymphocyte B cell response and further activates macrophages,
generating a second general response, which increases recruitment of eﬀector cells that can no longer be modulated by regulatory T cells and
resulting in the end in epithelial glomerular proliferation and fibrosis (10).
more important in the activation of previously diﬀerentiated
eﬀector T cells. An induced deficiency of ICOS reduces
autoantibody titers of IgG and in situ survival of T cells but
does not aﬀect the condition [16].
Natural inhibitors of the CD28/B7 pathway include the
cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor in T
cells and PD-1. Both of these recruit inhibitor protein ty-
rosine phosphatase (SHP-2). PD-1 chronically inhibits acti-
vated T cells and makes them respond in peripheral tissues
but not in lymphoid organs. This is essential in maintaining
T cell tolerance. The fine control between T regulator cells
and PD-1 pathway may depend on the completion of an un-
controlled reactive autoimmune response [17]. The PD-1
pathway has the ability to simultaneously remove self-
reactive T cells and promote the development of LT regulator
cells.
4. Genetic Susceptibility of SLE
Patients with SLE have defects in all branches of the immune
system including innate immunity, antigen presentation,
apoptosis, impaired tolerance in T and B cells, and defective
release of regulatory cytokines and chemokines. SLE should
be considered a failure of immune tolerance in one or more
of the central or peripheral checkpoints with summation
eﬀects ofmultiple genes related to the immune response [18].
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The tendency to self-reactivity is a natural phenomenon
as it is estimated that 75% of recently formed B cells in the
bone marrow in adults and 40% of the B cells located in
germinal centers are autoreactive [19, 20]. In murine models,
defects have been detected in both central and peripheral
tolerance in B and T cells by introducing self-reactive re-
ceptors [21]. However, in humans a natural selection mech-
anism is currently believed to be the major one for reducing
reactive immature B cells by as much as 75% in the bone
marrow [22]. An altered edition of this mechanism has been
reported in some patients with SLE. B cells that get through
this defective mechanism will be subjected to control in the
periphery by induced deletion, anergy, or apoptosis. Both
biological processes require strong BCR signals that activate
an inhibitory pathway via the CD22-tyrosine phosphatase
SHP-1 thus avoiding clonal amplification through the inhi-
bition of the interaction between B and Tfh cells [22].
For years now, human susceptibility to systemic autoim-
munity has been related to several genes with polymor-
phisms or mutations that encode defective proteins involved
in the immune system. HLA and non-HLA genes contribute
to the polygenic susceptibility of the disease, and about 30
genes have been consistently replicated and confirmed to
influence the predisposition of SLE. For instance, a genome-
wide association study (GWAS) evaluating 317,501 single
nucleotide polymorphisms (SNPs) in 720 women of Euro-
pean ancestry with SLE and 2,337 controls disclosed four loci
associated with the disease harboring the following genes:
ITGAM, KIAA1542, PXK, and the SNP rs10798269 in chro-
mosome 1q25.1 [23]. In addition to the already established
gene associations with SLE and other autoimmune diseases,
FCGR2A, PTPN22, and STAT4were confirmed. These results
are only an example to show that several genes, some with
known immune-related functions, predispose to SLE [23].
One of the most interesting genes associated with SLE
is PTPN22. This gene encodes for the protein tyrosine
phosphatase Lyp, in which a missense mutation that changes
residue 1858 from cytosine to thymidine (1858C/T) is asso-
ciated with multiple autoimmune disorders including SLE,
rheumatoid arthritis (RA), and type 1 diabetes (T1D) [24,
25]. The protein, encoded under normal circumstances, is
involved in B cell signaling. However, with the presence of
autoantibodies associated with the 1858T variant, B cell
signal transduction is impaired thus contributing to autoim-
munity.
A polymorphic variant of IRF5 has been linked to SLE
and high circulating levels of Type I interferon (IFN). The
genetic alterations may lead to sustained overproduction of
IFN αβ in human SLE, which will result in increased bi-
oavailability and activation of immature DCs that control
peripheral tolerance by deleting autoreactive lymphocytes
[26, 27]. IFN mature DCs activate and expand autoreactive
T cells thus helping autoreactive B cells to diﬀerentiate. In
addition to its indirect eﬀect through DCs, IFN also directly
allows the expansion and survival of CD4+ and CD8+ T cells
as well as the diﬀerentiation of B cells into plasma cells. The
increased frequency of autoreactive B cells depends on a
second set of genetic alterations that target B cell toler-
ance checkpoints. These early events create a first level of
autoimmune injury, which is clinically silent but might gen-
erate apoptotic cells and nucleic acid-containing immune
complexes. The capture of these apoptotic cells by myeloid
DCs and nucleic acid-containing ICs by peripheral DCs and
autoreactive B cells broadens the autoimmune reaction
thereby leading to disease manifestations [26, 27].
Many of the genes associated with more severe forms of
SLE such as HLA genes have also been associated with LN.
Certain alleles in the HLA-DR2 and the HLA-DQ haplotypes
seem to be particularly associated with LN in specific ethnic
groups [28, 29]. In addition, in a cohort of 2,366 patients
with SLE and 2,931 controls with common European an-
cestry, a variant at exon-3 (rs1143679 A) of Integrin-α-M
(ITGAM) was strongly associated (P < 0.0003) with renal
criteria in these patients. Among non-HLA genes associated
with LN, ITGAM has been consistently reported to influence
this SLE manifestation [30].
In African Americans, a strong risk factor has been
associated with the presence of a monocyte receptor poly-
morphism in FcγRII-H131 that interacts with IgG2, which
reduces the hepatosplenic clearance of circulating ICs [31].
In the context of the pathogenesis of LN, this may be impor-
tant because it will facilitate glomerular IC deposit (Table 1).
5. Pathogenesis and Antibodies
5.1. Glomerular Immune Complex Deposit and Anti-dsDNA.
An appropriate understanding of the current model of
glomerular immune complex deposit is based on several
experimental models of LN that use double-stranded anti-
DNA antibodies (anti-dsDNA) with diﬀerent aﬃnities and
physicochemical properties and correlate them in the eluate
of patients with LN.
Apparently, renal involvement begins with the glomeru-
lar ICs deposit. These ICs are predominantly antibodies
against single-stranded (ss) and double-stranded (ds) DNA
as well as some polyreactive reagents that include anti-Sm,
anti-RNP, anti-histones, anti-Ro/SS-A, anti-La/SS-B, and
anti-C1q antibodies [5]. The formation of ICs seems to be
predominantly in situ. However, although anti-dsDNA ICs
are present in LNmost of the time, it has not yet been proven
that these types of ICs are enough to induce LN [69].
Three mechanisms have been proposed to explain the
ability of anti-dsDNA to settle in the kidney [13]. First, anti-
dsDNA reactive antibodies can form ICs with DNA/nucle-
osome previously released from apoptotic cells. These ICs
may be deposited in the kidney and initiate an inflammatory
cascade. There is another postulated theory commonly
known as the planted antigen theory. This theory proposes
that anti-dsDNA reacts with DNA/ nucleosome trapped in
the glomerular base membrane (GBM). In addition, the
trapping of DNA/nucleosome has been associated with the
negatively charged DNA and positively charged GBM. The
third theory relates to the cross-reactivity between kidney
antigens and anti-dsDNA. Nephritogenic anti-dsDNA anti-
bodies have been shown to cross-react with alpha-actinin,
laminin, and heparan sulfate (Figure 2).
The amount of deposited ICs, isotypes, and their affin-
ity correlates with the severity of LN. The ICs located at
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Table 1: Adapted from [32] and [33]. Susceptibility genes in SLE associated with LN.
Chromosome Gene SNPs Population OR
1
with LN References
6p21 HLA region
DRB1∗0301
and several
other Alleles.
European, Several
Asian, African
American, mixed
European-
Amerindian, and
Latin American.
2.4 [29, 34–37]
7q32 IRF5
5bp promoter indel,
rs2004640,
rs2070197,
10954213
rs10954213
rs 729302
European, several
Asian, mixed
European-
Amerindian, African
American, Latin
american.
1.6 [23, 38–42]
2q32 STAT4
rs7574865,
rs3821236,
rs7582694
European, mixed
European-
Amerindian, several
Asian,
African-American
1.5 [23, 38, 40, 43, 44]
6q23 TNFAIP3
rs5029939
rs223096
rs223096
European, Asian,
African American
2.0 [23, 38, 40, 45–48]
16p11 ITGAM
rs9888739,
rs1143679,
rs4548893
European, mixed
European-
Amerindian, Asian,
African American,
Latin Americans
1.6
[30, 38–
40, 46, 49, 50]
4q24 BANK1
rs10516487
rs1726654
rs3733197
rs1051647
rs10516483
European, European-
Amerindian, Asian,
Caucasian
1.2 [38, 46, 51–53]
1p13 PTPN22 rs2476601
European, Latin
Americans
1.4 [23, 54]
8p23 BLK
rs13277113,
rs2736340
rs2248932
European, several
Asian
1.3
[23, 38–
40, 46, 55, 56]
2q37
PDCD
(CD279)
PD1.3A
European, European-
Amerindian, Chinese,
Latin Americans
1.2 [57]
1q25 TNFSF4
Risk haplotype;
rs3850641
European, Asian 1.4
[23, 38, 40, 46, 52,
58]
18q22.3 CD226
rs763361
rs727088
European, European-
Amerindian,
Asian
NA
2
[59, 60]
1q21–23 FCGR2A ARG131HIS
European, European-
Amerindian, African
American
2.2 [23, 39, 40]
19p13.2 TYK2
rs280519
rs2304256
rs12720270
European 1.2 [40, 42]
3p21.3 TREX1 rs72556554
European, Asian,
Hispanic, African
25 [61, 62]
Xq28
MECP2-
IRAK1
rs2269368
rs17435
rs3027933
rs1734791
European, Chinese,
Korean, European-
Amerindian
(Mexican)
1.4 [40, 63–65]
3p14.3 PXK
rs6445975
rs2176082
European 1.2 [23, 40]
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Table 1: Continued.
Chromosome Gene SNPs Population OR
1
with LN References
2q24 IFIH1 rs1990760 European NA
2
[40]
11p15.5
KIAA1542
(PHRF1)
rs4963128 European NA
2
[23]
8p23.1 XKR6 rs6985109 European NA
2
[23]
6q21 ATG5-PRMD1
rs6568431,
rs2245214
rs548234
European, Chinese NA
2
[23, 40, 66]
22q11.2 UBE2L3 s5754217 European, Chinese 1.2 [40, 45, 67]
5q33.3 PTTG1 rs2431099 European 1.2 [40, 45, 67]
6p21 UHRF1BP1 rs11755393 European NA
2
[40, 67]
5q32 TNIP1 rs7708392
European, Chinese,
Thai, Japanese.
1.3 [38, 40, 67, 68]
7p15.2 JAZF1 rs849142 European NA
2
[40, 67]
7p21.3 ICA1 rs10156091 European 1.2 [23, 67]
1q24 IL10 rs3024505 European NA
2
[40, 67]
1q25.3 NMNAT2 rs2022013 European, Chinese 1.1 [23, 38]
11q23.3 ETS1 rs6590330 Chinese, Thai NA
2
[38, 46]
10q11.23 WDFY4 rs877819 Chinese, Thai NA
2
[38, 46]
7p12.2 IKZF1 rs4917014 Chinese 0.7 [38]
12q24.32 SLC15A4
rs10847697
rs1385374
Chinese 1.31 [38]
2p22.3 RASGRP3 rs13385731 Chinese 0.64 [38]
OR1: Approximate odds ratio.
NA2: Data not available.
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Figure 2: Proposed theories for anti-dsDNA in situ immune complex deposit [13]. GBM: glomerular base membrane.
the mesangium and subendothelium subsequently contrib-
ute to the recruitment of inflammatory cells. Although there
is a predominant deposit of IgG and isotypes IgG2 and IgG3,
there are also IgM and IgA deposits as well as C3, C4, and C1q
molecules, which are part of the complement system [69].
The activation of the inflammatory cascade is achieved
through Fc gamma receptors in macrophages, DCs, neu-
trophils, mesangial cells, and kidney cells [70]. It is also
achieved by cross-reactivity with nephritogenic proteins ex-
pressed in renal parenchymal cells, PTEC, and mesangial
cells thus generating the release of proinflammatory medi-
ators and vascular adhesion molecules. Mesangial cells and
PTEC are the most involved in releasing cytokines such as
Interleukin-6 (IL-6), interleukin-1 (IL-1), tumoral necrosis
factor (TNF), and chemokines such as MCP-1 [71]. It is
worth highlighting that these nephritogenic compounds, as
has already been mentioned, are related to the expression of
laminin or collagen IV.
In addition, once ICs are deposited, they cannot be
phagocytosed by mesangial cells and so will be deposited in
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the subendothelium. This leads to the first migration and
posterior infiltration of monocytic eﬀector cells and poly-
morphonuclear cells (PMNs). This cell recruitment is mainly
mediated by the action of proinflammatory cytokines and
by the complement system thus causing tissue damage [12].
This, in turn, increases the release of more proinflammatory
cytokines (IL-1, IL-6, and TNF-α) and chemokines such
as MCP-1, secreted cytokine (RANTES), TNF-related weak
inducer of apoptosis (TWEAK), and activation of CAMs
(ICAM-1, VCAM-1), all of which enhance amplification of
the innate immune response. Moreover, the dysregulation
in the synthesis of cytokines could be responsible for me-
sangial proliferation, crescent formation, and progressive
glomerulosclerosis. The cytokines involved are IL-4, IFN-γ,
transforming growth factor (TGF), platelet-derived growth
factor (PDGF), and MCP-1 [12].
To support the idea that Fcγ receptors are directly in-
volved in the activation of the inflammatory cascade, LN has
been attenuated in the knockout models [72].
The adaptive immune response is simultaneously pro-
moted by the presence of ICs, which causes a reaction within
the DCs, and this induces the release of type I IFN. As a
result of the subsequent maturation of the DCs, antigens are
presented and infiltrating T cells undergo further activation.
This leads to amplification of Th2 responses, Th1, Th3, Th17
and B cells and further activates a new wave of eﬀector cells
such as monocytes and PMNs.
Based on murine models and neonatal studies in class V
NL (i.e., membranous), there is also an in situ glomerular
deposit of ICs. In this case, the antibody recognizes the recep-
tor of phospholipase 2 expressed in podocytes. However, the
target antigen in class V LN has not yet been identified.
The subepithelial ICs then trigger a cascade of events that
generate podocyte injury with flattening and sloughing
through the activation of the complement membrane attack
complex (MAC). Ultimately, this disruption is responsible
for proteinuria. In contrast to the endothelium and mesang-
ium, podocytes do not proliferate in response to injury but
produce thickening of the GBM due to increased synthesis of
extracellular matrix proteins [73].
Aside from anti-dsDNA being directly involved in in situ
IC formation, high-aﬃnity anti-DNA plays a central role
in some of the manifestations of SLE, especially LN. They
are relatively specific and are good markers of activity in
some patients. This has been confirmed in a large cohort of
1,000 patients reported by Cervera et al. [74]. Not all anti-
dsDNA antibodies are related to LN. As mentioned before,
this depends mainly on their specificity, aﬃnity, isotype
and idiotype, cross-reactivity with glycosaminoglicanos, and
ability to interact with nucleosomes or DNA-linked collagen.
The lack of IgM anti-dsDNA secretion is associated with ap-
parently more severe LN [75]. However, the disease can
develop in the absence of anti-dsDNA [13, 76].
5.2. Role of Complement in LN. Low total complement he-
molytic activity and decreased C3 and C4 levels are detected
in 75% of the patients with class III and 90% of those with
class IV LN. The settling of IgG isotypes, IgA, IgM, C1q,
C4, C3, and C5b-9 is called a full house, which is almost
exclusive to LN. Complement degradation products such as
C3d and C5b-9 can also be detected in urine thus providing
circumstantial evidence of the role of the complement system
in LN. However, C3 deficiency does not reduce the risk of
LN and its true role is unknown [70]. Some studies suggest a
predominant mechanism via Fcγ receptors [12, 77].
5.3. Antinucleosomes. Chromatin is the complex of histone-
native DNA in eukaryotic cells. It is the packaging unit of
DNA and controls the expression of genetic information by
regulating access to transcription factors. There has been
increasing evidence that nucleosomes are the main targets of
the IC deposits [78].
Apparently, antinucleosome complexes adhere to hep-
aran sulfate and have been detected in the human glomeru-
lus. The main source of nucleosome release is from lympho-
cyte apoptotic bodies. It seems that they are generated at a
very early stage even before DNA is released [79].
Free DNA has very few antigenic properties. It becomes
more immunogenic as DNA-protein complexes show tridi-
mensional epitopes of chromatin. Several histone fractions
are shown to be able to bind glycosaminoglican proteins.
It seems likely that the immune response begins with anti-
nucleosome and anti-DNA antibodies and is the result of
epitope amplification response. When these complexes are
given to murines, they cause a lupus-like syndrome (SLE-
like) [80]. Histone DNA complexes have a higher aﬃnity for
glycosaminoglycans in vitro and serve as a histone anchor
for a larger deposit of DNA. Kalaaji et al. demonstrated an-
tichromatin deposits in human and murine lupus LN by
electron microscopy [81, 82]. This chromatin appeared to
originate from glomerular apoptotic cells.
5.4. Anti-C1q. In 2004, Trouw et al. demonstrated in a
mouse model that antibodies against C1q of the complement
system (anti-C1q) play a pathogenic role in LN in the pres-
ence of ICs [83]. Anti-C1q could participate in glomerular
injury by reducing the clearance of circulating ICs.
5.5. Alterations in Apoptosis. In healthy individuals, dead
cells, mainly T and B cells as well as PMNs, are rapidly re-
moved by macrophages in a noninflammatory context. In
SLE patients, poor clearance of apoptotic bodies leads to the
release of self-antigens that are subsequently submitted to T
cell presentation by follicular DCs and B cells in secondary
lymphoid organs thus challenging peripheral self-tolerance
[84].
In 1998, mice exposed to syngeneic apoptotic thymocytes
intravenously induced development of ANAs, anticardi-
olipin, and anti-ssDNA antibodies as well as deposits of ICs
in the kidney [85]. Some of the autoantibodies generated
react with nuclear products as a result of degradation by
granzymes present in membrane vesicles of apoptotic cells
[86]. This leads to the release of DNA-histone complexes,
free DNA, small RNA, SS-A SS-B, and overexpression of
phospholipid molecules in the membrane. The clearance of
apoptotic cells is finely regulated through the activation of
multiple receptors in phagocytic cells (scavenger receptor,
phosphatidylserine receptors) that detect apoptotic cells
8 Autoimmune Diseases
[87]. A decreased ability on the part of macrophages to clear
apoptotic bodies in a considerable number of patients has
been previously described. This appears to be a defect since
they have diminished phagocytic capacity at diﬀerent stages
of maturation [88, 89]. This defect alters the balance of
peripheral tolerance and generates a first phase of autoim-
mune activation leading to a reaction of natural autoreactive
B cells with subsequent epitope amplification [90].
A slight increase in apoptosis at the tubule-interstitial
level that correlated with mononuclear infiltrates in 35 kid-
ney biopsies of patients with LN was reported. In addition
to these findings, the level of apoptosis of tubular cells had a
positively significant statistical correlation with the activity
index score for mononuclear cell infiltration but not with
scores for other chronicity index components [91].
5.6. Dendritic Cells in LN. DCs are themost powerful antigen
presenting cells (APCs) and are crucial in both innate and
adaptive immune responses [92]. DCs are classified as type I
or tolerogenic cells, which release interleukin 10 (IL-10), and
type II or immunogenic cells, which release interleukin 12
(IL-12).
DCs are found in peripheral tissues where they capture
antigens and then migrate to lymph nodes to exert their APC
function on follicular helper T cells (fhT) by regulating the
activation and diﬀerentiation of cell populations. They can
also interact directly with B cells. DCs descend from two
lines, myeloid and lymphoid. They diﬀer in the expression of
toll-like receptors (TLRs). Lymphoid DCs release cytokines
such as IL-12 and IL-18. Myeloid DCs (mDCs) are the largest
population and are diﬀerentiated from monocytes. Their
synthesis rises in bacterial infections. Moreover, DCs can
synthesize multiple cytokines and chemokines such as IL-
1, IL-6, IL-8, IL-12, IL-18, granulocyte macrophage colony
stimulating factor (GM-CSF), MCP-1, IL-10, and TGF. DCs
are considered to be the largest producers of IL-18 and
promote lymphocyte Th1 responses [92].
DCs are crucial for maintenance of immune tolerance.
Circulating immature DCs capture antigens and migrate to
lymph nodes, where they present self-peptides in the absence
of costimulatory signals to T cells, which induce their anergy
or deletion [93].
Human DCs instruct naı¨ve CD4+ T cells to become IL-
21-producing Fh T cells through the secretion of IL-12 [92].
IL-21 is a B cell growth factor required to induce diﬀeren-
tiation and isotype switching and cooperates with IL-6 and
the B lymphocyte stimulator (BlyS). In turn, IL-12 appears
to induce both Th1 γ interferon production as well as IL-2
[92].
In SLE, DCs are activated by self-antigens through TLR
3, 7, 8, 9 or Fcγ receptors and are induced to release IFN-α,
a crucial molecule in autoimmunity that also plays a key role
in LN [94].
Several subtypes of DCs are detected in normal human
kidneys, predominantly the myeloid cells. Only 25% of them
are plasmacytoid DCs (BDCA2 +). In murine models of LN,
DCs in GBM are increased in NZB mice. In proliferative
forms of murine LN, a population increase has been shown
in CD68+ myeloid/macrophage cells at the glomerular
interstitium [85] as well as an increase in lymphoid DCs
[95, 96]. Apparently, the extent of infiltration is higher in
proliferative classes. Most of the DCs detected in LN are
immature in contrast to SLE patients that show a marked
reduction of mature DCs and lymphoid cells [95]. This could
be the consequence of their migration to the kidneys and
other tissues during the activity of the disease.
LN has been attributed to an imbalance between cytokine
homeostasis and IC deposits. High synthesis of cytokines
and chemokines by DCs may contribute to LN pathogenesis.
Therefore, the increased migration of DCs, which has been
recognized in the kidneymay be due to the early release of IL-
18, IL-1, and C-C chemokine receptor type 5 (CCR5) [97].
These, in turn, are central in regulating the secretion of more
cytokines and chemokines and determining the prevalence of
the response of Th1 and Th2 cells.
5.7. Role of T and B Cells in LN Pathogenesis
5.7.1. T Lymphocytes. T cells are divided into eﬀectors and
regulators. The former includes CD4+ Th1, Th2, Th3, cyto-
toxic CD8+, and Th17. Regulator T cells include (FOXP3+
CD25+) T cells and natural killer T cells (NKs) [97]. Togeth-
er, these cells participate in initiation, amplification, and reg-
ulation of the immune response in LN as well as migration,
destruction, fibrosis, resolution, and exacerbations of the
disease [97]. Therefore, they have become one of the targets
for therapeutic intervention [97].
Central defects detected in SLE patients not only include
the substitution or replacement of the T cell receptor
(TCR)/CD3δ by TCR/Fcγ [97] but also display constitutive
changes in the grouping of lipid vesicles that carry tran-
scription factors with the consequence of early aberrant TCR
signaling [98] and decreased threshold of activation. The
molecular mechanisms of the above mentioned are not clear
but appear to be both transcriptional and posttranscrip-
tional modifications. In SLE, the entry of calcium activates
calcineurin, which, in turn, activates the nuclear factor of
activated T cells (NFAT) thus increasing the expression of
CD40L and stimulating B cell activation and the synthesis of
immunoglobulins [98].
In LN, activated CD4 and some CD8 T cells as well as
activated macrophages and DCs infiltrate the renal intersti-
tium, thus worsening renal function [99]. The restricted use
of Vβ chains on recruited T cells suggests their oligoclonality
and are potentially specific antigens or autoreactive [100].
Crispı´n et al. reported infiltrates of double negative (DN)
T cells and Th17, which were presumably derived from a
population of blood-producing IL-17 DN T cells [101]. T
memory CD45RO+ expressing cells were also detected in the
urine of patients with LN [102].
It is worth mentioning that DN T cells constitute a small
population (less than 5%) in healthy subjects and are signif-
icantly increased in patients with SLE [101]. Having a mixed
profile of Th1, Th2, and Th17, they synthesize IL-4, IL-17,
IL-1, and IFN-γ. DN T cells are also found in patients with
LN. However, why this cellular diﬀerentiation happens is not
yet clear.
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In LN, T cells are able to interact with epitopes like nu-
cleosome histone complexes. T cells also help autoreactive
nephritogenic B cells, modulate the diﬀerentiation of T cell
subpopulations, recruit macrophages and NK cells, and in-
duce renal cell damage through the release of cytokines or
direct cytotoxicity [103]. T cells also activate proximal tubu-
lar cells and promote parenchymal fibrosis [103].
CD40 and CD40L interaction between B and T cells
induces clonal expansion, which makes diﬀerentiation into
plasma cells (isotype switching) possible. Interestingly, the
use of CD40L monoclonal antibodies (mAb) in NZB mice
has been shown to delay the onset of the disease, reduce
the number of B cells, suppress the isotype switching, and
decrease the titles of anti-DNA antibodies [104].
At first, clarifying the role of Th1 and Th2 cells in murine
LN was given great importance but their biological or genetic
modulation showed some inconsistent results [105]. Both
populations appear to contribute to a greater or lesser extent
since giving both IL10 and IFN-γ to the NZ and WNZ
(BWF1) hybrid mice accelerated nephritis, and antagonism
of the two delays the disease as the antagonism of IL-4 or
IFN-γ does in MRL mice [105]. However, there is evidence
of a mayor predominance of the role played by Th1 cells
in the pathogenesis of LN since the lymphocytic infiltration
is abolished in the knockout model [106, 107]. The IFN-
γ, in contrast, facilitates the interaction between T cells
and parenchymal cells, especially PTEC, and increases the
expression of HLA class II and accessory molecules [16].
Some of these contradictory results seem to depend on
the confusing eﬀect generated by the action of Th17 cell
products, which are, in turn, promoted by the action of IL-6,
IL-23, and TGF-β [108].
When IL-18 is administered to mice, LN is accelerated
and the accumulation of DN T cells is fostered. As a result,
IFN-γ is synthesized and DN T cells are diﬀerentiated into
CD4+ cells and CD8+ cells. IL-18 antagonism reduces lym-
phoproliferation, production of IFN-γ, and progression of
LN thus also implying a role for Th1 cells [109]. In addition,
serum levels of IL-18 nearly double in patients with LN [110].
Microarray analysis suggests that production of nephri-
togenic autoantibodies in murine models depends on Th1
cells [111]. IFN-γ promotes the switch from IgG2 to IgG3,
which is typical of LN unlike a predominance of IgG1 in
the skin in SLE [112]. Therefore, IFN-γ seems to be crucial
in modulating the activity of LN in murine models and
promoting the synthesis of IgG2 in MRL-Faslpr and NZB
mice [111].
Likewise, the expression of genes in infiltrating kidney T
cells strongly suggests the presence of dominant Th1 though
there is also some expression of Th2 GATA-3 cells (tran-
scription factor) [113]. Chan et al. reported T bet (Th1
transcription factor) overexpression, IFN-γ, IL-2, IL-12, IL-
18, MCP-1, and IL-10, which had a significant correlation
with the histological activity index of LN [113]. Therefore,
measurement of pro-Th1 in urine can be a promising
biomarker for LN activity. This pro-Th1 response appears to
be associated with proliferative LN class III and IV [114] and
induces the switch towards Th1 response. This apparently
worsens the disease and correlates with the histological
activity index [115, 116]. In contrast, Th2 response appears
to be predominant in Type Vmembranous LNmodels [117].
Nevertheless, the role of T cells in humans in the course
of LN is less clear, and it cannot be resolved on the basis of
murine models of gene deletion or costimulation. Other
authors have confirmed the proliferative LN Th1 dominance
in humans [114, 115]. However, in pediatric LN, a balance
between Th1/Th2 on the basis of IgG subclasses has been
detected [118, 119]. In proliferative LN, there is overexpres-
sion of TNF-related apoptosis-inducing ligand (TRAIL) in
the glomerular tubules of patients [120]. These findings may
play a protective role by enhancing PTEC survival while also
exerting a proinflammatory eﬀect that may contribute to
local inflammation and injury by inducing expression of
ICAM-1 and IL-8, which may also be caused by TNF-α and
IFN-γ [120].
5.7.2. B Lymphocytes. B cells are also abnormal and hyper-
active in SLE. The uncontrolled activation of B cells may be
the result of aberrant editing, increased signaling, an increase
in co-stimulatory receptors B7 and CD40, increased subpop-
ulations of plasmablastic DCs and plasma cells in the blood,
and alterations of cytokines (BAFF, IFN-α, IL-6, and IL-21).
The B-cell-activating factor (BAFF) rescues autoreactive B
cells from deletion and induces isotype switching to IgG
[121–124].
There has recently been a resurgence of interest in the
role played by eﬀector B cells not only through the synthesis
of autoantibodies but also as regulators. To support this,
some autoimmune models that were thought to be primarily
mediated by T cells have shown potential roles for B cells
through gene deletion or administration of CD20 mono-
clonal antibody in mice (independent autoantibody eﬀects)
[125].
B cells can also modulate some cellular responses by
direct interaction with memory T cells and regulation of
DC development. Indirectly, B cells are involved in cytokine
synthesis: IL-10, IL-4, IL-6, IFN-γ, IL-2, IL-12, IL-23, IL-
27, and BAFF. Under inflammatory conditions, they can
function as B regulatory cells by releasing IL-10 and TGF-β
through TLR stimulation. The increase in plasmablastic cells
and B lymphopenia has been correlated with SLE clinical
activity [125].
In humans, B cells seem to have some degree of orga-
nization rather than being random. Formation of ectopic
germinal centers with organized follicles and DCs that cor-
relate with the severity of tubule interstitial disease and
deposit of ICs has been demonstrated as well [126]. However,
to some authors, there is a predominance of the APC phe-
notype rather than synthesis of immunoglobulins as well
as an increased expression of receptors for chemokine-type
CXCR5 BCA-1 [127].
One of the most recent findings regarding B cells relates
to circulating levels of BAFF (BLyS) in SLE, RA, and Sjo¨gren’s
syndrome (SS). BAFF seems to contribute to B cell survival in
germinal centers in a high percentage of patients and in NZB
and MRL models. In these, it correlates with the amount of
proteinuria and anti-DNA levels. BAFF acts synergistically
with IL-6 and IL-21 to foster survival and diﬀerentiation of B
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cells in humans. It is synthesized by monocytes, neutrophils,
DCs, and T cells [128, 129].
Interestingly, in transgenic murine models with BAFF
over expression, there is an induced lupus-like syndrome
with LN even in the absence of T cells [130, 131]. For some
reason, it appears to mostly favor the maturation of autore-
active clones. Both plasmablastic and plasma cells express the
receptor that is involved in the homeostasis of peripheral B
cells [132].
Results from a GWAS pointed to B cell having an impor-
tant role in the development of SLE through signaling and
the involvement of TLR 7 and TLR 9 [67]. In SLE, the role
of T cell regulators CD4+CD25 + Fox P3 has been demon-
strated to suppress activity of B cells in vitro and in vivo [133].
5.7.3. Th17 Lymphocytes (LTh17). LTh17 are a subpopula-
tion of CD4+ T cells and a subtype of high-producing IL-
17 derived from Th1 cells [134]. LTh17 do not lend them-
selves to regulation by T regulator cells (Tregs) [135]. LTh17
do not lend themselves to regulation by T regulator cells
(Tregs) [136]. The diﬀerentiation of naive cells into this
proinflammatory Th17 subtype apparently occurs inversely
to the development of Treg cells. Although both populations
are induced by TGF-β, Th17 require the presence of inflam-
matory signals like IL-6, IL-21, and IL-23 as well in order
to favor their diﬀerentiation and inhibit the Treg cells. In
humans, it seems Th17 cells also synthesize IFN-γ.
When Th17 cells produce IL-17 in response to TGF-β,
they activate kappa beta nuclear factor (κβNF). Conse-
quently, a MAP kinase cascade is generated and activates the
ROR transcription factor [135]. This exerts a powerful
proinflammatory eﬀect and fosters increased recruitment of
macrophages and neutrophils thus inducing the production
of IL-8 and MCP-1. ROR transcription factor also induces
CAM expression on T cells and the production of IL-6 and
GM-CSF. This is how a second phase of inflammation is gen-
erated and becomes self-perpetuated. Th17 subpopulations
do not appear to be antigen specific [135].
Zhao et al. evaluated IL-17 serum levels in fifty-seven
patients with confirmed SLE and 30 healthy volunteers [137].
They found significantly elevated levels in patients with SLE.
However, there was no positive association with activity
of the disease measured by Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI), which indicates that there
is still no concluding data regarding the role of Th17 and SLE
and, therefore, LN [137, 138].
5.7.4. T Regulatory Cells. The concept that Treg play an im-
portant role in maintenance of autoimmune response is
well accepted. A decreased number and function of Treg
cells implicated in murine lupus have been shown. However,
human studies, many of which appear to be the result of
clinical activity or immunosuppressive therapy [139, 140],
are inconclusive [141, 142].
5.7.5. T Cells and Adhesion Molecules. Cell adhesion mole-
cules seem central and CD44 is greatly increased in patients
with SLE [143]. Through alternative splicing and posttrans-
lational mechanisms, this gene has several isoforms such
as CD44v3 and CD44v6 that are high in SLE patients and
correlate with the disease activity and the presence of LN.
Infiltrating T cells express these isoforms. Patients with active
NL have high urinary concentrations of VCAM-1. Their ex-
pression is regulated by IL-1 and TNF [144].
5.8. Eﬀector Cells and Molecules. In proliferative LN, there
is predominance of mononuclear infiltrates and, to a lesser
extent, of neutrophils and platelets. Mononuclear activation
depends on chemokines, complement system activation, and
ICs and cause cytotoxicity in the target organ. When there is
cytotoxicity, mononuclear cells become eﬀector cells [97].
Also involved in LN immunopathogenesis, proteases that
have been detected in urine of LN patients are presumably
involved in the degradation of extracellular matrix proteins
of the GBM and mesangium (serine proteases, elastases, cat-
hepsin G, and collagenases) thus generating tissue necrosis
[97].
In LN, many PMNs are located close to the crescents and
their proteases and oxygen radicals and derivatives of nitro-
gen may contribute to tissue damage and necrosis. One of
the proteases, collagenase B-associated lipocalin has recently
been reported as a good biomarker of active LN [97].
In addition to releasing free radicals, nitric oxide, and
proteases, macrophages also release proinflammatory cytok-
ines such as IL-1, TNF-α, and IFN-α, PDGF, TGF-β, com-
plement components, coagulation factors, and chemokines
[97].
There is a prominent recruitment of type II activated
macrophages mainly in the tubules, interstitium, and glom-
eruli both in murine models and in humans [145]. Their
activation may also be enhanced during Th1 responses. The
release of growth factors by macrophages may contribute to
mesangial proliferation (PDGF and TGF β) and sclerosis in
LN and MRL [146, 147].
5.9. Role of Intrinsic Renal Cells in LN. The main intrinsic
kidney cells include mesangial, endothelial, and epithelial
cells. Apparently, they are not innocent bystanders but may
be signal amplifiers. This has been observed in murine mod-
els and appears to contribute on three levels: proinflamma-
tory mediator release, fibrogenesis, and possibly APC.
Kidney mesenquimal cells (mesangial, tubular epithelial,
and endothelial cells) synthesize and release significant
amounts of MCP-1. They may also overexpress α actinin in
the presence of IFN γ and IL-1. All of the above has been
previously shown in murine models [148].
5.10. Cytokines, Chemokines, and LN. Although the picture
is still unclear in terms of proinflammatory molecules, an
upregulation of cytokines such as TNF, IL-1, IL-6, IL-18,
IFN-γ, and IL-4, induce Th1 and Th2, cells, respectively. In
contrast, a downregulation of TGF-β in an inflammatory
context has been proven [149].
5.11. Interferon α. IFN type I or α is produced by all cell types
but particularly by DCs in response to viral stimuli and in
the presence of ICs [150]. Both pathways act by stimulating
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the TLRs types 3, 7, 8, 9 and thus induce maturation in
DCs through the increase in the expression of costimulatory
molecules such as ICAM-1, CD86, HLA class I and class
II molecules. IFN-α activates hundreds of genes including
viral transcripts (OAX, MX1), the IFN regulatory factor
(IRF) 5 and IRF7, BLyS, chemokines (MCP-1 and IP-10) and
enhances Th1 responses by inducing the synthesis of IFN-γ
and expression of CXCR3 cells. IFN-α is a potent inducer of
BlyS [151].
In SLE patients, a microarray analysis of thousands of
genes has shown an over expression of IFN-α-inducible genes
in about 40% of patients [152]. Specifically, three inducible
genes showed a high IFN score and had a significantly higher
prevalence of renal disease, increased SLE activity and pres-
ence of antibodies specific to Ro, U1 RNP, Sm, and ds-DNA
but not phospholipids [94]. Steroid pulses dramatically de-
crease IFN-α expression by inducing significant depletion of
pDC but their action is of short duration (one week) [153].
IFN-α seems to be a potent inducer of mesangial prolif-
eration in the kidney, and several studies report that IL-6 is a
critical mediator of the production of human nephritogenic
antibodies [154].
5.12. IFN-γ in LN. It has been suggested that, in addition to
inducing in situ synthesis of autoantibodies, IFN-γ increases
the expression of CD40 molecules as well as that of MCP-
1, ICAM-1, and VCAM-1. This seems fundamental in the
pathogenesis of exacerbations of LN.
Recent recognition of the role of pro-Th1 cytokines such
as IL-18, IL-12, and IL-27 makes this molecule central to
the regulation of these responses [155]. According to mul-
tiple studies, higher circulating levels of IL-18 are found in
patients with SLE and LN and may be crucial in the devel-
opment of Th1 responses [156].
5.13. Interleukin 10. In patients with SLE, high levels of IL-
10 are from three to twelve times higher than in controls, but
there seem to be little correlation with the disease activity
[157].
5.14. Transforming Growth Factor β. TGF-β ligands signal
and activate intracellular eﬀectors thus regulating transcrip-
tion. TGF-β is a cytokine involved in both normal renal
function and the development of glomerulosclerosis. It is
produced by NKs, lymphocytes, monocytes, macrophages,
and renal mesangial cells. It also has a stimulatory eﬀect on
T cells and a downregulatory eﬀect on antibody production.
In human SLE, several studies demonstrated the nephrotoxic
eﬀects of TGF-β within kidney cells. There is a strong rela-
tionship between expression of TGF-β and podocyte deple-
tion and apoptosis. TGF-β also increases epithelial to mes-
enchymal cell transdiﬀerentiation, induces peritubular capil-
lary loss, and causes glomerular endothelial cell apoptosis.
In contrast, the cytoprotective eﬀects are mediated by the
hepatocyte growth factor (HGF). Therefore, studies found
that the balance between TGF-β and HGF seems to be an
important prognostic factor in LN TGF-β and HGF [158,
159].
5.15. Interleukin-4. The IL-4 role in the synthesis of autoan-
tibodies in murine models and in humans is controversial
in LN [160, 161]. It also seems to promote the depositing
of collagen type III in human mesangial cells and could
contribute towards renal failure progression [162]. CD4+
cells, which produce IL-4 in patients with Class III and Class
IV LN, were demonstrated by immunohistochemistry [163].
5.16. Chemokines. Ex vivo monocytes have shown increased
synthesis of chemokines that correlate with SLE activity:
interferon-gamma-induced protein 10 (IP-10), RANTES,
monokine induced by IFN-gamma (MIG), MCP-1, and IL-
18. They also seem to correlate with LN activity as does IL-8
[164].
Of the above molecules, the best studied is MCP-1 and
more recently TWEAK. Chemokines not only play a prepon-
derant role in inducing and regulating the selective chemoat-
traction but also participate in the regulation of cellular acti-
vation and exert angiogenic, fibrogenic, and hematopoietic
eﬀects.
There is increasing evidence that MCP-1 plays a role in
the progression of renal failure based on diﬀerent mouse
models and in various proliferative LN [148, 165]. In murine
knockout MRL, there is marked prolongation of survival and
nomonocytic or lymphocytic infiltrates. They seem to be the
initiator of locally produced early tubule interstitial damage.
As a result, MCP-1 is synthesized mainly by mesangial cells
but also endothelial, mononuclear, and tubular epithelial
cells and excreted in the urine. Therefore, MCP-1 in the urine
of patients is a promising biomarker of LN activity [166].
In addition to its chemoattractant and releasing properties
on mononuclear cells, MCP-1 appears to play a role in situ
in inducing renal tubular and mesangial cells to synthe-
size proinflammatory cytokines such as IL-6, adhesion mol-
ecules, for instance, ICAM-1, and promote transcription of
NF κβ by PKC [165]. In addition to that, MCP-1 promotes
mesangial and endocapillary proliferation.
Chemokine receptors on T cells participate in regulating
their traﬃcking. Native T cells express primarily CCR4,
which interacts with chemokine C-X-C motif ligand 12
(CXCL12). Its pathogenic role has gained much attention
recently. There is over expression in kidneys from NZBW,
MRL, BXSB models as well as in LN in humans [167]. The
use of murine C-C chemokine receptor type 4 (CCR4)
antagonists has reduced the number of phenotypes and the
use of C-C chemokine receptor type 3 (CCR3) antagonists
reduced the infiltration of LTh1 and LTh17 and, therefore,
the production of IFN-γ [168].
High expression of CXCR3 in 60% of infiltrating cells
in biopsy material at the tubule-interstitial level has been
recently reported in human type IV LN [169]. The CXCR3
receptor is a great candidate to explain the influx of LTh1 cells
in LN. There are three CXCR3 ligands (CXCL9, CXXL10,
CXCL11) with CXCL10 (IP-10) being the most potent
inducer of IFN-γ synthesis. It has been proven to be a major
chemokine expressed early on or preceding inflammation in
murine LN [170, 171]. It is produced by endothelial cells,
fibroblasts and monocytes stimulated with IFN-γ. In human
LN, it appears to identify class IV nephritis [134]. In SLE
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patients, levels of IP-10 are very high and correlate signifi-
cantly with the histological activity index. The expression of
CCR5 may also play a role in Th1 chemotaxis [40]. CXCL16
is among other chemokines involved [172].
5.17. TNF Superfamily Cytokine (TWEAK). This is widely
expressed in human kidneys, specifically in mesangial cells,
podocytes, and tubular cells. It is a proximal inducer of
chemokine release. It also induces proliferation of mesangial
cells and podocytes [173]. TWEAK has been recently studied
as a biomarker for LN, and results have shown promising and
significant results [174].
In summary, it is, therefore, possible that the deposit of
ICs triggers the release by mesangial and tubule interstitial
cells of MCP-1, TWEAK, and proinflammatory cytokines,
which will contribute to the chemotaxis and after that, acti-
vation of monocytes and macrophages. This activation, in
turn, releases chemokines such as CXCL10, which favors type
LTh1 chemotaxis. LTh1 chemotaxis releases IFN-γ, which
amplifies a further increased production of proinflammatory
cytokines by monocytes and promotes IgG2 and IgG3 sub-
class synthesis. These immunoglobulins are responsible for
generating anti-DNA antibodies, which induce glomerular
cell proliferation.
6. Pathology
Classification of LN is critical to the issue of patient care and
helps the physician make therapeutic decisions, follow up
on the patient, and compare outcome results. In May 2002,
a consensus conference of nephrologists, pathologists, and
rheumatologists was held in order to redefine the diﬀerent
LN classes, and the meaning of the pathology terminology
in order to standardize the way biopsies are interpreted and
reported by diﬀerent centers worldwide [175] (Table 2). The
detailed pathological characteristics and their descriptions
are beyond the scope of this paper. Readers are invited
to consult pertinent and recent references about this topic
[176].
6.1. Tubulointerstitial Disease. Active glomerular lesions have
abundant interstitial inflammatory infiltrates of CD4+ cells
and some CD8+ T cells, abundant monocytes, and plasma
cells [99], which correlate with glomerular filtration rate and
creatinine levels [177]. Others have found correlation be-
tween interstitial IC and serological activity [162]. Typically,
the tubular damage, fibrosis, and atrophy are related linearly
with renal function and are less responsive to treatment.
These lesions often coexist with Classes III and IV.
7. Recent Advances in LN Therapy
LN impacts the clinical outcome of SLE both directly, in the
form of target organ damage, and indirectly, through adverse
eﬀects of therapy [178]. On the other hand, the histological
patterns of LN provide the basis for therapeutic guidelines
and decisions to prevent target organ damage, as they are
predictive. Despite improvements in survival rates and ESRD
as mentioned before, LN is a marker of a bad prognosis
[179]. Recent advances in therapy include a number of ran-
domized controlled trials (RCTs), in which the goal has been
to achieve clinical eﬃcacy by inducing a remission of LN
while at the same time minimize severe side-eﬀects of treat-
ment. The concept of two phases of therapy, an induction
phase and amaintenance phase, is still widely accepted [180].
Patients with Class II LN and I do not require directed
immunosuppressive treatment, and usually maintenance of
adequate blood pressure control and blockade of the rennin
angiotensin aldosterone system is the cornerstone of treat-
ment. Patients with LN treated with ACE inhibitors have
a better rate of renal involvement-free survival at 10 years
(88.1%) as compared to patients with ACE inhibitors with
a rate of renal involvement-free survival at 10 years of 75.4%
(P < 0.01) [181].
7.1. Induction Therapy for Proliferative LN. Most patients
with active proliferative LN are initially treated with a pulse
of an intravenous steroid followed by a high-dose oral
steroid, or by this method in conjunction with other im-
munosuppressive agents. These include cyclophosphamide,
mycophenolate mofetil, and azathioprine.
7.1.1. Cyclophosphamide (CY). RCTs held at the National
Institutes of Health (NIH) have provided strong evidence for
the eﬃcacy of IVCY in the treatment of proliferative LN. An
IVCY pulse (0.5–1 g/m2) each month for six consecutive
months followed by a follow-up pulse of low-dose corticos-
teroid every third month has been shown to be eﬀective and
prevent relapses better than a shorter regimen limited to the
six monthly doses of IVCY alone [182].
The Euro-Lupus Nephritis Trial (ELNT) was a multicen-
ter European RCT in which 90 patients with proliferative
LN were randomized to either high-dose IVCY (0.5–1 g/m2)
in 6monthly pulses followed by two additional quarterly
doses or to low-dose IVCY (500mg) every 2 weeks to a
total of 6 doses followed by azathioprine (AZA) maintenance
therapy (2mg/kg daily). After a median follow-up period of
41 months, there was no diﬀerence between the two groups
in the rate of achievement of renal remission or in the rate of
renal relapse [183]. The results of the ELNT of the follow-up
period (73 months) showed similar results [184].
7.1.2. Mycophenolate Mofetil (MMF). The active metabolite
of MMF suppresses B- and T-cell proliferation due to the
absence of the salvage pathway necessary for DNA synthesis.
That is the reason why results of several recent controlled
trials have led to MMF being recommended as one of the
first-choice regimens for inducing a remission in active
proliferative LN. Chan et al. [185] randomized 42 patients
with diﬀuse proliferative LN to either 12 months of oral
MMF (2 g daily for 6 months followed by 1 g daily for 6
months) or to 6 months of oral CYC (2.5mg/kg daily) fol-
lowed by oral AZA (1.5mg/kg/day) for 6 months, and both
groups also received oral prednisolone (0.8mg/kg). After a
median follow-up period of 12months, there were no signifi-
cant diﬀerences between the remission rates (81 versus 76%),
partial remission rates (14 versus 14%), or relapse rates
Autoimmune Diseases 13
Table 2: International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification of LN [175].
Class I minimal mesangial lupus nephritis
Normal glomeruli by light microscopy, but mesangial immune deposits by immunofluorescence.
Class II mesangial proliferative lupus nephritis
Purely mesangial hypercellularity of any degree or mesangial matrix expansion by light microscopy, with mesangial immune deposits. May
be a few isolated subepithelial or subendothelial deposits visible by immunofluorescence or electronmicroscopy, but not by light microscopy.
Class III focal lupus nephritis
Active or inactive focal, segmental, or global endo- or extracapillary glomerulonephritis involving <50% of all glomeruli, typically with focal
subendothelial immune deposits, with or without mesangial alterations.
Class IV diﬀuse lupus nephritis
Active or inactive diﬀuse, segmental, or global endo- or extracapillary glomerulonephritis involving ≥50% of all glomeruli, typically with
diﬀuse subendothelial immune deposits, with or without mesangial alterations.
This class is divided into diﬀuse segmental (IV-S) lupus nephritis when ≥50% of the involved glomeruli have segmental lesions, and diﬀuse
global (IV-G) lupus nephritis when ≥50% of the involved glomeruli have global lesions. Segmental is defined as a glomerular lesion that
involves less than half of the glomerular tuft. This class includes cases with diﬀuse wire loop deposits but with little or no glomerular
proliferation.
Class V membranous lupus nephritis
Global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence or
electron microscopy, with or without mesangial alterations. Class V lupus nephritis may occur in combination with class III or IV in which
case both will be diagnosed Class V lupus nephritis show advanced sclerosis
Class VI advanced sclerosis lupus nephritis
≥90% of glomeruli globally sclerosed without residual activity.
(15 versus 11%) for both treatments; however, infections
were less common in the MMF group.
The Aspreva LupusManagement Study (ALMS) reported
by Appel et al. [186] was one of the largest RCTs of a treat-
ment of proliferative LN ever reported involving 370 patients
with WHO class III, IV, or V LN randomized to 24 weeks of
treatment with either MMF (3 g daily) or IVCY (0.5–1 g/m2).
Both groups were also treated with prednisolone that started
at 60mg daily and was tapered. After 6 months of therapy,
there was no significant diﬀerence between the two groups
in the combined complete remission plus partial remission
rates. Moreover, there was no diﬀerence in mortality between
the two groups, and a total of 14 of the 370 patients died
[186].
Overall, RCTs have shown no real diﬀerence in induction
therapy for LN between CY and MMF in terms of complete
and partial remission rates. However, infection rates as ad-
verse events of immunosuppressants are lower with the use of
MMF leaving to the physician’s choice whether to start MMF
or CY as induction therapy in order to achieve remission and
prevent progression of renal disease.
7.1.3. Tacrolimus. Recent findings regarding treatment in
LN involve tacrolimus, which is a macrolide calcineurin in-
hibitor that potently suppresses human T-cell proliferation
by inhibiting the intranuclear translocation of cytoplasmic
nuclear factors in activated T cells by binding to tacrolimus-
binding proteins and inhibiting calcineurin. Miyasaka et al.
[187] reported a RCT that was undertaken to evaluate the
eﬃcacy and safety of tacrolimus in patients with persistent
LN patients treated with a glucocorticoid. This RCT showed
significant decrease in LN disease activity index (LNDAI)
with tacrolimus when compared to placebo. A case-control
study conducted by Szeto et al. [188] compared tacrolimus
with standard protocols of oral CYC or AZA for the treat-
ment of class V LN. Complete remission rate and partial re-
mission rate were 38.9% and 44%, respectively, in the tacrol-
imus group, and 36.8% and 57.9%, respectively. It is impor-
tant to remark that no significant adverse eﬀects occurred in
the tacrolimus group.
Five open-label prospective studies of the treatment of
LN have been conducted [189–193], with preliminary evi-
dence regarding the use of tacrolimus as induction-phase
therapy. However, there is a need to conduct RCT with more
proliferative LN patients in order to evaluate results and
establish tacrolimus as on-label frequent use for the treat-
ment of LN.
7.2. Maintenance Therapy for Proliferative LN. Maintenance
therapy for proliferative LN focuses on maintaining renal
remission previously achieved in the induction therapy. By
avoiding flares or relapses, progression of renal disease can
be achieved and, therefore, ESRD. TheMAINTAINNephritis
Trial [194], conducted on 105 patients with proliferative
LN, was randomized to maintenance-phase therapy with
AZA (target dose 22mg/kg daily) or MMF (target dose 2 g
daily). The MAINTAIN Nephritis Trial was predominantly
Caucasian, and the results may not be applicable on pop-
ulations of diﬀerent ethnicities. Some meta-analyses have
unequivocally favored the additional benefit of treating with
immunosuppressive agents during the maintenance phase of
LN therapy [195–197]. The selection and dosage in order
to reduce long-term toxicities especially in childbearing age
women must be done along with the patient. In addition,
it is important to highlight the role of corticosteroids as
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a major component of treatment in the maintenance phase
of LN therapy, despite the side eﬀects of long-term steroid
use.
7.3. New Agents for the Treatment of Lupus Nephritis
7.3.1. Rituximab. This biological agent is a chimeric half
murine-half human monoclonal antibody directed against
the B cell marker CD20. Label indications of this biologic
agent include RA and more recent SLE. Catapano et al. used
Rituximab to treat 31 patients with relapsing or refractory
SLE, 2 of whom developed relapsing/refractory LN during
treatment with Rituximab (375mg/m2/week for 4 weeks in
one patient and 1000mg × 2 doses in the other) [198]. After
a 30-month follow-up period, peripheral B cells had been
depleted in 97% of the patients, and a remission had been
achieved in 87% of the patients (complete in 17 and par-
tial in 10) [198]. A renal remission occurred in 10 of the
11 patients with active LN. Clinical improvement was mani-
fested by reductions in disease activity, proteinuria, and daily
prednisolone dose. A relapse occurred in 67% of the patients
treated after a median interval of 11 months. In 50% of the
patients who experienced a relapse, the relapse was associated
with the return ossf circulating B cells. A second course of
treatment with rituximab was eﬀective. A recent systematic
review, which covered the period from 2002 to 2007, demon-
strated that 171 (91%) of the 188 patients with SLE treated
with rituximab for severe, refractory disease had a significant
improvement in at least one lupus manifestation, and 94
(91%) of the 103 patients with LN exhibited a therapeutic
response [199].
There is more need for RCTs using biological agents such
as rituximab and other agents that are in course of study
like Belimumab and Abatacept. One may infer due to the
important role of B cells and T cells in LN pathogenesis that
directed target therapy against them could bring new insights
for eﬀective treatment in LN.
8. Conclusion
LN is considered to be the major complication or outcome in
SLE. Its incidence varies widely between populations. Over
the years, a better understanding of immunopathogenesis
and natural history has developed, which ultimately results
in eﬀective therapeutic decisions for the benefit of the pa-
tient and prevent end-stage renal disease. In addition, this
appropriate comprehension of NL gives hope to future
therapy aimed directly towards specific cells, autoantibodies,
cytokines, and chemokines in order to regulate inflammation
and tissue injury.
LN results from a complex interaction between autoan-
tibodies in association with anti-dsDNA, nucleosomes and
histones that end up forming kidney ICs and permanently
activated inflammatory cells that stimulate and induce prolif-
eration in local cells, which, in turn, stimulate complement,
cytokines and chemokines.
So far, therapy for LN has shown to be partially eﬀective
in terms of renal remission. Directed target therapy against B
and T cells could bring new insights for real eﬀective treat-
ment in LN and thus achieving a better outcome in patients.
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